Schering Corporation

Albert W Buchholz, Jr

Craig D Boyle

Kevin Joseph Klopfer

Ilia A Zavialov

Hoa N Nguyen

Cecilia A Orr

Vilas H Dahanukar

Funcheng Zhang

Jeffrey M Skell

Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those shown in FIGS.and, respectively, and which exhibit differential scanning calorimtery profiles substantially the same as those shown in FIGS.and, respectively, and are represented by the formula:  Pharmaceutical compositions comprising the polymorph Form 1 or 2 of Compound 13 and at least one excipient or carrier, and methods of using the polymorph Form 1 or 2 of Compound 13 to treat a variety of physiological disorders, such as erectile dysfunction.

Xanthine phosphodiesterase V inhibitor polymorphs

Growing community of inventors

Bridgewater, NJ, United States of America

Albert W Buchholz, Jr